key: cord-0706978-ykh0byxw authors: Bos-Liedke, Agnieszka; Cegla, Paulina; Matuszewski, Krzysztof; Konstanty, Ewelina; Piotrowski, Adam; Gross, Magdalena; Malicki, Julian; Kozak, Maciej title: Differences among [(18)F]FDG PET-derived parameters in lung cancer produced by three software packages date: 2021-07-06 journal: Sci Rep DOI: 10.1038/s41598-021-93436-w sha: dfe99cefac92118150abb6ecf1c1611b8ab75a3a doc_id: 706978 cord_uid: ykh0byxw Investigation of differences in derived [(18)F]FDG PET metabolic and volumetric parameters among three different software programs in lung cancer. A retrospective analysis was performed on a group of 98 lung cancer patients who underwent a baseline [(18)F]FDG PET/CT study. To assess appropriate delineation methods, the NEMA phantom study was first performed using the following software: Philips EBW (Extended Brilliance Workstation), MIM Software and Rover. Based on this study, the best cut-off methods (dependent on tumour size) were selected, extracted and applied for lung cancer delineation. Several semiquantitative [(18)F]FDG parameters (SUV(max), SUV(mean), TLG and MTV) were assessed and compared among the three software programs. The parameters were assessed based on body weight (BW), lean body mass (LBM) and Bq/mL. Statistically significant differences were found in SUV(mean) (LBM) between MIM Software and Rover (4.62 ± 2.15 vs 4.84 ± 1.20; p < 0.005), in SUV(mean) (Bq/mL) between Rover and Philips EBW (21,852.30 ± 21,821.23 vs 19,274.81 ± 13,340.28; p < 0.005) and Rover and MIM Software (21,852.30 ± 21,821.23 vs 19,399.40 ± 10,051.30; p < 0.005), and in MTV between MIM Software and Philips EBW (19.87 ± 25.83 vs 78.82 ± 228.00; p = 0.0489). This study showed statistically significant differences in the estimation of semiquantitative parameters using three independent image analysis tools. These findings are important for performing further diagnostic and treatment procedures in lung cancer patients. www.nature.com/scientificreports/ Imaging data and processing methodology are specific to each institution and have changed over the years due to the introduction of new techniques and software for PET/CT image interpretation. In 2013, Sansone et al. performed a study in which the use of different software programs for SUV measurement was examined 5 . Three different software programs in only two patients were each analysed, and the results showed that the distribution of SUV differs among packages. However, the researchers did not alter the timecourse analysis. Different approaches were shown by Arain et al., who compared four software packages and assessed the differences in various SUV values in 100 patients 6 . Their study concluded that although different software programs should not be used interchangeably in clinical practice, the differences in SUV values among them were small. Recently, Wilson et al. reviewed PET/CT images among four different FDA-approved software packages and found significant differences in SUV max values among them 7 . One of the most widely used packages of various applications is MIM Software (MIM Encore version 6.8.8, MIM Software Inc. Cleveland, OH, USA 8 ). This tool is used in 3D [ 18 F]FDG PET image analysis in a variety of medical areas, namely, oncological diagnostics and therapy, neurology and radionuclide dosimetry 9, 10 . In 2017, Breault et al. used this software in the analysis of [ 18 F]florbetapir PET standard uptake value ratios (SUVr) in patients suspected of having Alzheimer's disease 11 . Phillips EBW (version 4.0.2.145, Philips Medical Systems Nederland B.V., the Netherlands 12 ), implemented commercially with Phillips PET/CT scanners, is mainly used in oncology for diagnosis and treatment planning 13, 14 . Authors have also reported the value of this package in neurology 15 and recently in COVID patients 16 21 . The aim of this study was to compare values of [ 18 F]FDG PET parameters obtained using three different commercially available software packages for PET image analysis (Philips EBW, MIM Software and Rover) in a group of previously untreated NSCLC patients. Such a comparison using the mentioned software has not been performed previously, especially on heterogeneous groups of patients. Moreover, the majority of papers compare only SUV values; thus, we decided to expand these findings by examining other PET/CT parameters that are routinely used in the clinic. In the whole group of patients, a very strong correlation was found in SUV max values in BW, Bq/mL and LBM among all three software programs and in SUV mean BW and LBM, while a moderate correlation was found in SUV mean values in Bq/mL among all three software programs (Tables 1 and 2 ). Another strong correlation was found between Rover and MIM Software in TLG (Bq/mL) value (r = 0.9863) and in MTV (BW) value (r = 0.9830) ( Tables 3 and 4) . Mean values for all assessed parameters in all three software programs are shown in Table 5 . Statistically significant differences were found in SUV mean (LBM) between MIM Software and Rover No other statistically significant differences were shown in any other assessed parameters among the software programs. In the present study, we examined the differences among [ 18 F]FDG PET metabolic and volumetric parameters (SUV max , SUV mean , TLG and MTV) obtained from three software packages that are commercially available, namely, Philips EBW, MIM Software and Rover. The major finding included significant differences (p < 0.005) in SUV mean (LBM) between MIM Software and Rover and in SUV mean (Bq/mL) between Rover and Philips EBW (p < 0.005) and Rover and MIM Software (p < 0.005). Moreover, the MTV value showed significant differences (p = 0.0489) between MIM Software and Philips EBW. Additionally, strong correlations in SUV max values (BW and Bq/mL, LBM) and SUV mean (BW, LBM) among all three software packages were obtained. Furthermore, a strong correlation was found between Rover and MIM Software for MTV (BW) values (r = 0.9830) and TLG (Bq/mL) values (r = 0.9863). SUV is a normalized concentration of a radiopharmaceutical in a lesion of interest. Since both the patient's BW and LBM can be used for normalization, both options should be examined along with the nonnormalized uptake value (Bq/mL). SUV max is the maximal value among the voxels included in the region of interest (ROI), so it is completely independent of ROI definition but susceptible to noise 22 . Currently, because SUV max is less dependent on the observer and is at the same time more reproducible, SUV max is used more frequently than SUV mean 22-24 . It was shown that different pathological types and sizes of NSCLC produce SUV max values of different magnitudes in PET scans [25] [26] [27] . Moreover, the tumour differentiation of adenocarcinoma as well as the size of all NSCLCs can be impeccably predicted using SUV max in [ 18 F]FDG PET/CT, as demonstrated by Karam et al. 28 . Authors showed that a linear regression analysis of SUV max from tumour size dependency could adequately distinguished adenocarcinoma from squamous cell carcinoma. Due to the small number of patients in our study, we did not distinguish NSCLC subtypes, so we cannot confirm or deny these findings. However, we do not exclude further analysis on a larger group of patients in the future. SUV max strongly predicts not only lung cancer but also other types of cancers. It is important to mention multiple articles that focused on SUV max [ 18 F]FDG PET analysis in pretreated primary tumours for the prediction of the occurrence of neck metastasis in oral cancer 29 , head and neck squamous cell carcinoma 30 and others 31, 32 . Despite strong evidence showing the scientific and medical value of SUV max , it should be noted that some other studies have revealed no correlation between SUV max and tumour recurrence 33 . The SUV max values in our study were strongly correlated among each other in BW, Bq/mL and LBM in all three software programs, so it remained the most significant parameter for lung cancer prediction. SUV max is based www.nature.com/scientificreports/ on a single voxel, which is the least observer-and ROI definition-dependent but strongly influenced by image noise 34 ; therefore, this result should not be surprising. Nevertheless, this indicates that our work is significant for each study focusing on this type of prediction not only in lung cancer but also in other types of malignancies. SUV mean incorporates information from multiple voxels, making it highly dependent on voxels that are included in the analysis; thus, it is less sensitive to image noise 35 . In contrast to SUV max , it is rarely used as a metabolic biomarker, and only limited data exist to support it in this role. However, in several publications, the authors outlined the possible importance of SUV mean . It was shown, for instance, that an increase in the pretreatment SUV mean of the primary tumour was associated with decreased disease-free survival (DFS) 36 . Moreover, a relative change in SUV mean of more than 40% between baseline and after therapy was shown to differ by 2 years in overall survival, DFS and locoregional control 36 . Nevertheless, the authors outlined that SUV max was a better predictor of disease outcome. It was also shown that SUV mean assessed by [ 18 F]FDG PET and supported by global hepatic glycolysis can reflect hepatic functional capacity. Authors have shown that this parameter can be used as a potential imaging diagnostic factor in assessing diffuse pathology of the liver 37 . Moreover, the relationship of both SUV mean and SUV max of [ 18 F]FDG PET with an increasing number of metabolic syndrome components in visceral adipose tissue that are associated with vulnerability to atherosclerosis was recently described by Pakh et al. 38 . These are only a few recently reported possible applications of SUV mean . According to the described data, nonnormalized SUV mean values are highly differentiated among the three software programs used that raise questions about the consistency of the analysed parameters. Several studies have shown some inaccuracies in the SUV mean value due to variations in ROI definition 22, 39 . To eliminate those inaccuracies, we used the average Th value over all software according to the specific size of the primary tumour. There are a limited number of articles concerning SUV differences among available software packages. The most similar to our work is a study published in 2015 by Pierce et al. 40 in which they showed substantial differences in SUV (BW) from a phantom study among tested PET/CT systems, which is in contrast to the results of this work. The authors would like to draw the readers' attention to several limitations, such as investigation of single parameter (SUV (BW)), lack of clinical data (random noise) and small voxel size, that could have had a significant influence on the results of this project. Investigations of changes in SUV values in patients were also presented by Brendle et al. 41 and Hirji et al. 42 . Brendle et al. assessed the reproducibility of SUV values among different reconstruction methods (3D OSEM + TOF and PSF-reconstruction + TOF) and matrix sizes (3D OSEM: 200 × 200 and 400 × 400) in a cohort of 27 patients with different types of cancer. They found that SUV max , SUV mean and SUV peak do not differ significantly among themselves between different PET reconstruction methods. However, doubling the matrix size showed a tendency towards higher SUV values 41 . Hirji et al. analysed 25 patients to determine whether uptake in the aorta varies among different reconstruction algorithms. The homogeneity of the analysed group of patients was not defined. The differences in reconstructions between SUV max or blood pool SUV mean and target-to-background ratio were not statistically significant. However, qualitative analysis showed differences between IT + TOF and UHD or UHD + MAR reconstructions; therefore, harmonization of those techniques was recommended 42 . In both works, the homogeneity of the patient group was questionable, and the number of analysed patients was relatively small. Conversely, the different histological tumour types may influence the analysed parameters. These limitations are in contrast to our study, in which all data were obtained on homogenous groups of NSCLC patients using the same reconstruction and the same matrix size to keep from influencing the PET parameters. MTV together with TLG are volumetric PET parameters using a threshold-based volume of interest 43 . Since according to the current 8th TNM classification, tumour volume plays a crucial role in cancer staging, an analysis performed in a group of cancer patients is meaningful. Therefore, in our study, a phantom study was performed first, and the same threshold (dependent on the tumour size) was used in all three software programs. Based on our analysis, we found a strong correlation in MTV among all three software programs. However, significant differences (p = 0.049) in this parameter were shown only between MIM Software and Philips EBW. Liu et al. 44 showed that MTV differs significantly between patients with EGFR mutations and with wild-type EGFR. Shrestha et al. 45 found that among all semiquantitative PET parameters, only MTV showed prognostic ability in patients with stage I NSCLC treated with carbon-ion radiotherapy. They also concluded that MTV histological variation may need consideration for risk-adapted therapeutic management 45 . Other authors suggest that MTV is a prognostic factor for local control (LC) and overall survival (OS) in patients with early-stage NSCLC 46 . MTV is also widely used for assessing gross tumour volume in radiotherapy planning not only in lung cancer patients but also in patients with other cancers 47 ; therefore, based on our study, it is reasonable to assess patients on workstations with the same software to avoid under-or overestimating the results. Currently, there is increased interest in TLG, which is a product of SUV mean and MTV. It consists of both metabolic and volumetric information. Several studies have shown that TLG is a prognostic factor in lung cancer patients 48, 49 . In our study, we found significant differences in SUV mean and MTV between the assessed software programs; however, no differences were noted in TLG values, which might be caused by the small number of patients included in this analysis. The results of this work emphasize the requirement for meticulous analysis of depicted PET effects. One can see that the difference between [ 18 F]FDG PET metabolic and volumetric parameters obtained in NSCLC (and not only) using different software programs can be crucial. Therefore, it should be emphasized that in pretreatment and even post-therapy analyses, parameters obtained from different software programs can be compared only qualitatively, and quantitative analyses should be harmonized 50, 51 . To the best of our knowledge, this is one of the very few studies that assess not only SUV values but also volumetric parameters (such as MTV and TLG) in a homogenous group of patients and not in a phantom study. The NEMA phantom study was used to identify the best cut-off method and corresponding optimal threshold value for primary tumour delineation in each software. The procedure was repeated for different tumour volumes represented by different sphere radii in the NEMA phantom. Afterwards, for each tumour volume, an average threshold over three software programs was calculated ( Table 1 ). The averaged thresholds (Th) were used for all further evaluations in all three software programs. The purpose of the averaging procedure is to replicate standard clinical practice where the threshold values are taken from the literature and do not always represent the optimal value for a specific software. Evaluation. Several 52 SUV in units of Becquerel's per millilitre (Bq/mL) is nothing other than the measured uptake in the investigated ROI. All PET parameters were estimated using BW, LBM (except Philips EBW, which does not have this value in their workflow) and Bq/mL. The MTV was defined as the volume of the PET-positive tumour region. It was computed as the sum of the delineated tumour voxels (using an appropriate threshold Table 6 ) times the volume per voxel. An example of the delineation method based on one of the patients included in the analysis is shown in Fig. 1 . Furthermore, TLG was calculated as a product of SUV mean and MTV. The normality of the data distribution was checked using the W Shapiro-Wilk test, and a p-value less than 0.05 was considered significant. Additionally, a Pearson correlation coefficient was used to compare parameters among software programs. A very strong correlation was assumed with values ranging from 0.7 to 1, a strong correlation ranging from 0.5 to 0.7, a moderate correlation ranging from 0.3 to 0.5 and a low correlation ranging from 0 to 0.3. The results of this work emphasize the requirement for meticulous analysis of depicted PET effects. The SUV mean and MTV values showed the most significant differences among the assessed software programs. It should be noted that the difference between [ 18 F]FDG PET metabolic and volumetric parameters obtained in NSCLC patients using different software programs might have an influence on further diagnostic and treatment procedures. GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries Methods for staging non-small cell lung cancer: diagnosis and management of lung cancer, 3 rd ed: American Collage of Chest Physician evidence-based clinical practice guidelines Cancer of the lung pleura and mediastinum Revised ESTS guidelines for preoperative mediastinal lymph node staging for non-small cell lung cancer Assessment of standardised uptake values in PET imaging using different software packages comparison of SUV parameters across four commercial software platforms Comparison of PET/CT SUV metrics across different clinical software platforms at UNMH Comparison of commercial dosimetric software platforms in patients treated with 177 Lu-DOTATATE for peptide receptor radionuclide therapy Feasibility of rapid integrated radiation therapy planning with follow-up FDG PET/CT to improve overall treatment assessment in head and neck cancer Correlation between two methods of florbetapir PET quantitative analysis. Am FDG PET/CT for rectal carcinoma radiotherapy treatment planning: comparison of functional volume delineation algorithms and clinical challenges Image quality and diagnostic performance of a digital PET prototype in patients with oncologic diseases: initial experience and comparison with analog PET 18F)-FDG PET/CT in essential tremor: preliminary results FDG-PET/CT findings highly suspicious for COVID-19 in an Italian case series of asymptomatic patients Feasibility and performance of novel software to quantify metabolically active volumes and 3D partial volume corrected SUV and metabolic volumetric products of spinal bone marrow metastases on 18F-FDG-PET/CT Feasibility and utility of ROVER software for 3D quantitative image analysis of FDG-PET in patients with diffuse large B-cell lymphoma (DLBCL) Inter-observer variability using ROVER® software for processing of cerebral FDG-PET studies Quantification of TMJ rheumatoid arthritis on positron emission tomography scans using rover software. Oral Surg. Oral Med. Oral Pathol Treatment monitoring by 18F-FDG PET/CT in patients with sarcomas: interobserver variability of quantitative parameters in treatment-induced changes in histopathologically responding and nonresponding tumors FDG PET/CT interobserver agreement in head and neck cancer: FDG and CT measurements of the primary tumor site Lodge, repeatability of SUV in oncologic 18F-FDG PET FDG PET-CT in non-small cell lung cancer: relationship between primary tumor FDG uptake and extensional or metastatic potential Maximum standard uptake value of mediastinal lymph nodes on integrated FDG-PET-CT predicts pathology in patients with non-small cell lung cancer Absence of a relationship between tumor 18f-fluorodeoxyglucose standardized uptake value and survival in patients treated with definitive radiotherapy for non-small-cell lung cancer Correlation of quantified metabolic activity in nonsmall cell lung cancer with tumor size and tumor pathological characteristics Maximum standardized uptake value (SUV max ) of primary tumor predicts occult neck metastasis in oral cancer Pretreatment FDG-PET standardized uptake value as a prognostic factor for outcome in head and neck cancer Prognostic value of metabolic information in advanced gastric cancer using preoperative 18 F-FDG PET/CT The prognostic value of SUV max measuring on primary lesion and ALN by 18 F-FDG PET or PET/CT in patients with breast cancer SUV and segmentation: pressing challenges in tumour assessment and treatment FDG-PET/CT imaging biomarkers in head and neck squamous cell carcinoma Analysis of pretreatment FDG-PET SUV parameters in head-and-neck cancer tumor SUV mean has superior prognostic value Early FDG PET at 10 or 20 Gy under chemoradiotherapy is prognostic for locoregional control and overall survival in patients with head and neck cancer Mean standardized uptake value (SUVmean) and global hepatic glycolysis as potential imaging markers reflecting hepatic functional capacity: evidence from 18F-FDG PET/CT Characterization of glucose uptake metabolism in visceral fat by 18 F-FDG PET/ CT reflects inflammatory status in metabolic syndrome Impact of different standardized uptake value measures on PET-based quantification of treatment response A digital reference object to analyze calculation accuracy of PET standardized uptake value Is the standard uptake value (SUV) appropriate for quantification in clinical PET imaging?-Variability induced by different SUV measurements and varying reconstruction methods Effect of PET image reconstruction techniques on unexpected aorta uptake The effect of different segmentation methods on primary tumour metabolic volume assessed in 18F-FDG-PET/CT in patients with cervical cancer, for radiotherapy planning The role of metabolic tumor volume (MTV) measured by [18F] FDG PET/CT in predicting EGFR gene mutation status in non-small cell lung cancer Prognostic significance of semi-quantitative FDG-PET parameters in stage I non-small cell lung cancer treated with carbon-ion radiotherapy Metabolic tumour volume is prognostic in patients with non-small-cell lung cancer treated with stereotactic ablative radiotherapy Metabolic tumor volume and conformal radiotherapy based on prognostic PET/CT for treatment of nasopharyngeal carcinoma Metabolic tumor volume measured by F-18 FDG PET/CT can further stratify the prognosis of patients with stage IV non-small cell lung cancer Prognostic value of total lesion glycolysis in stage III/IV small cell lung cancer Multicentre analysis of PET SUV using vendor-neutral software: The Japanese Harmonization Technology (J-Hart) study Harmonization of standardized uptake values between two scanners, considering repeatability and magnitude of the values in clinical fluorine-18-fluorodeoxyglucose PET settings: a phantom study Optimum lean body formulation for correction of standardized uptake value in PET imaging This research received no external funding. The authors declare no competing interests. Correspondence and requests for materials should be addressed to P.C.Reprints and permissions information is available at www.nature.com/reprints.Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.